Clopidogrel Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Antiplatelet Treatment Preferences of a Group of Cardiologists from T ürkiye: A Survey Research Study
CONCLUSION: The aim of this survey to capture a snapshot of the preferences of a group of cardiologists in Türkiye regarding DAPT treatment and duration. The responses were both in accordance and in conflict with the current guidelines.PMID:38465531 | DOI:10.5543/tkda.2023.54778 (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - March 11, 2024 Category: Cardiology Authors: Özge Çetinarslan Mustafa Yener çağ Mehdi Zoghi As ım Oktay Ergene Source Type: research

Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke
This randomized clinical trial evaluates the use of dual vs single antiplatelet therapy in the treatment of patients with mild to moderate ischemic stroke. (Source: JAMA Neurology)
Source: JAMA Neurology - March 11, 2024 Category: Neurology Source Type: research

The effect of argatroban on early neurological deterioration and outcomes in minor ischemic stroke: preliminary findings
ConclusionIn patients with MIS, argatroban administration and reaching the target APTT can reduce the incidence of END and improve short-term functional prognosis. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - March 8, 2024 Category: Neurology Source Type: research

Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease
Antiplatelet therapy with aspirin and/or one of the P2Y12 inhibitors (e.g., clopidogrel, prasugrel, and ticagrelor) is the cornerstone of medical therapy to mitigate the risk of ischemic events in patients with atherosclerotic cardiovascular diseases (ASCVD) [1]. Moreover, dual antiplatelet therapy (DAPT) is the standard of care following percutaneous revascularization of coronary, lower extremity and carotid arteries [2 –4]. Clopidogrel is the most widely used P2Y12 inhibitor but requires hepatic activation by the cytochrome P450 (CYP) 2C19 enzyme [5]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 8, 2024 Category: Hematology Authors: Sina Rashedi, Parham Sadeghipour, Junyang Lou Source Type: research

Is Platelet Reactivity Testing in PAD patients undergoing endovascular therapies ready for routine clinical use?
Endovascular therapy (EVT) is indicated in symptomatic lower extremity peripheral arterial disease (PAD) patients however, restenosis and stent thrombosis pose therapeutic challenges for these patients. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used after EVT to reduce both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Despite the widespread use of DAPT and more potent P2Y12 inhibitors such as ticagrelor and prasugrel, patients continue to experience recurrent ischemic events, specifically stent thrombosis and re-stenosis after EVT. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 6, 2024 Category: Cardiology Authors: Madhan Shanmugasundaram Tags: Editorial Source Type: research

Is Platelet Reactivity Testing in Patients With Peripheral Arterial Disease Who Underwent Endovascular Therapies Ready for Routine Clinical Use?
Endovascular therapy (EVT) is indicated in patients with symptomatic lower extremity peripheral arterial disease (PAD); however, restenosis and stent thrombosis pose therapeutic challenges for these patients. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used after EVT to reduce both major adverse cardiovascular events and major adverse limb events. Despite the widespread use of DAPT and more potent P2Y12 inhibitors such as ticagrelor and prasugrel, patients continue to experience recurrent ischemic events, specifically stent thrombosis and restenosis after EVT. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 6, 2024 Category: Cardiology Authors: Madhan Shanmugasundaram Tags: Editorial Source Type: research

Clopidogrel versus newer P2Y12 inhibitors in the dual antiplatelet therapy for stent-assisted coil embolization of intracranial aneurysms: A meta-analysis
CONCLUSION: In patients who underwent a SACE, newer P2Y12 inhibitors showed no differences in intraoperative and follow-up complications compared with clopidogrel.PMID:38439698 | DOI:10.1177/15910199241236821 (Source: Interventional Neuroradiology)
Source: Interventional Neuroradiology - March 5, 2024 Category: Radiology Authors: S ávio Batista Raphael Camerotte Agostinho C Pinheiro Igor Costermani Anthony Bishay Jos é Alberto Almeida Filho Lucca B Palavani Edmundo Damiani Bertoli Raphael Bertani Jason A Ellis Yafell Serulle Christian Ferreira Source Type: research